Testing MIL116 in healthy people and those with IgA Nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called MIL116 for IgA Nephropathy. First, healthy volunteers will test the drug's safety, then people with IgA Nephropathy will see if it can help reduce protein in their urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For healthy volunteers: You must be 18 to 55 years old, weigh at least 110 pounds, and have a BMI between 19 and 32.
- For people with IgA Nephropathy: You must have a kidney biopsy confirming the disease and have protein in your urine (at least 0.75 grams per day).
- You must be on a stable dose of certain blood pressure medications (ACE inhibitors or ARBs) for a while before joining.
- You cannot have received certain immune-suppressing drugs (like rituximab or cyclophosphamide) in the last 3 to 6 months.
- You cannot have very high protein in your urine (over 3.5 grams per day) or other severe kidney conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HS-10390, to see if it can help people with IgA nephropathy. You may qualify if you have the condition, are on stable blood pressure medication, and meet certain kidney function and lab criteria.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help protect kidney function. Participants must have a recent kidney biopsy showing certain features and stable kidney function.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
Hear when a new Immunoglobulin A Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.